A 12-week, phase 2A, randomized, subject and investigator blinded, placebo-controlled trial to evaluate the safety, tolerability and efficacy of CE-326,597 [CE-326597] on glucose control and body weight in overweight adult subjects with type 2 diabetes mellitus.

Trial Profile

A 12-week, phase 2A, randomized, subject and investigator blinded, placebo-controlled trial to evaluate the safety, tolerability and efficacy of CE-326,597 [CE-326597] on glucose control and body weight in overweight adult subjects with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2013

At a glance

  • Drugs CE 326597 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Mar 2012 Actual end date changed from Nov 2008 to Feb 2009 as reported by European Clinical Trials Database.
    • 15 Mar 2012 Additional location (Bulgaria) added as reported by European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top